Elrexfio produces median OS of >2 two years in R/R MM in single-arm phase II study

Former CDER Director Patrizia Cavazzoni named Pfizer chief medical officer, executive vice president

Patrizia Cavazzoni will rejoin Pfizer Inc. as chief medical officer and executive vice president.

February 28, 2025

Kimberly Stegmaier appointed chair of pediatric oncology at Dana-Farber

Kimberly Stegmaier was named chair of Pediatric Oncology at Dana-Farber Cancer Institute and associate chief of the Division of Hematology/Oncology at Boston Children’s Hospital. Her appointment is effective April 1.

February 21, 2025

Vol.51 No.07

In Brief

Jason Damsker and Michael Noonan join Fox Chase

Jason A. DamskerMichael NoonanJason A. Damsker was appointed professor in the Department of Hematology/Oncology and Michael Noonan was appointed assistant professor in the Supportive Oncology and Palliative Care Program at Fox Chase Cancer Center.

February 21, 2025

Vol.51 No.07

Clinical Roundup

Talzenna + Xtandi improve OS in metastatic castration-resistant prostate cancer, phase III study finds

Pfizer Inc. announced positive results from the phase III TALAPRO-2 study of Talzenna (talazoparib), an oral poly ADP-ribose polymerase inhibitor, in combination with Xtandi (enzalutamide), an androgen receptor pathway inhibitor, demonstrating a statistically significant and clinically meaningful improvement in overall survival compared to placebo plus Xtandi in patients with metastatic castration-resistant prostate cancer, with or without homologous recombination repair gene mutations.

February 14, 2025

Vol.51 No.06

Drugs & Targets

EU, China approve Sarclisa + standard of care for MM

The EU has approved Sarclisa (isatuximab-irfc) in combination with a standard-of-care regimen, bortezomib, lenalidomide, and dexamethasone, for the treatment of adult patients with newly diagnosed multiple myeloma ineligible for autologous stem cell transplant, based on data from the IMROZ phase III study.

January 24, 2025

Vol.51 No.03

Clinical Trials & Tribulations

Chadi Nabhan: Why I wrote a book about cancer

Almost all of us who have practiced oncology for years have encountered situations where we have had to counsel caregivers and guide them throughout their loved ones’ journeys. We have faced patients who took complementary therapies to an extreme; some to a point where they wouldn’t share what they were taking for fear that we might demand they stop.

January 17, 2025

Vol.51 No.02

By Chadi Nabhan